{"gene":"EAF2","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2002,"finding":"EAF2 (ELL-associated factor 2) physically interacts with ELL RNA polymerase II elongation factor; endogenous EAF2 and ELL co-immunoprecipitate from multiple cell lines and co-localize in a nuclear speckled pattern by confocal microscopy. EAF2 binds to the amino-terminal domain of ELL (distinct from the carboxy-terminal domain that binds EAF1). EAF2 contains a transcriptional activation domain in its serine/aspartate/glutamate-rich region. MLL-ELL fusion protein retains the EAF1 interaction domain but not the EAF2 interaction domain.","method":"Co-immunoprecipitation from multiple cell lines, confocal microscopy, deletion mutagenesis, transcriptional activation assay, retroviral bone marrow transduction","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reciprocal Co-IP from multiple cell lines, mutagenesis mapping of interaction domain, orthogonal localization data, transcriptional activation assay; single lab but multiple orthogonal methods","pmids":["12446457"],"is_preprint":false},{"year":2005,"finding":"EAF2 is a downstream target gene of noncanonical (beta-catenin-independent) Wnt-4 signaling in Xenopus laevis. EAF2 is specifically expressed in the developing eye and its expression depends on Wnt-4 function. Loss-of-function of EAF2 causes loss of eyes, and EAF2 overexpression can rescue loss of Wnt-4 function. In neuralized animal caps, EAF2 regulates expression of the eye-specific transcription factor Rx, consistent with a role as an RNA polymerase II elongation factor.","method":"Morpholino knockdown, mRNA rescue injections, in situ hybridization, Xenopus laevis loss-of-function assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with morpholino and gain-of-function rescue in Xenopus, multiple orthogonal methods establishing pathway position downstream of noncanonical Wnt-4","pmids":["15775981"],"is_preprint":false},{"year":2006,"finding":"ELL binding is required for nuclear speckle formation of EAF2, stabilizes EAF2 protein, and enhances its transactivation activity. ELL binding therefore controls EAF2 intracellular localization, stability, and transcriptional function.","method":"Co-transfection, co-immunoprecipitation, protein stability assay, transactivation assay","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, stability assay, and transactivation assay in single lab with multiple orthogonal methods","pmids":["16114057"],"is_preprint":false},{"year":2007,"finding":"The region of EAF2 (amino acids 68–113) is necessary and sufficient for both ELL binding and for induction of apoptosis and growth suppression in prostate cancer cells. Co-expression of EAF2 and ELL leads to significantly increased cell death and growth suppression, indicating that ELL interaction is essential for EAF2's apoptotic and tumor-suppressive functions.","method":"Transfection of deletion mutants, colony formation assay, co-immunoprecipitation","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis mapping of functional domain with co-IP validation and apoptosis assay, single lab","pmids":["17044034"],"is_preprint":false},{"year":2007,"finding":"Homozygous or heterozygous knockout of EAF2 in mice results in high rates of lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma, and prostatic intraepithelial neoplasia. EAF2 deficiency in the mouse prostate enhances cell proliferation and increases epithelial cell size, and the knockout mice also exhibit cardiac cell hypertrophy, establishing EAF2 as a tumor suppressor with roles in growth suppression and cell size control in multiple tissues.","method":"Murine knockout model (homozygous and heterozygous), histopathology, cell proliferation analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout model with defined multi-organ tumor phenotype, replicated across multiple tissue types in same study","pmids":["17873910"],"is_preprint":false},{"year":2009,"finding":"EAF2 physically binds to pVHL (von Hippel-Lindau protein) via its NH2-terminus (EAF2) and both alpha and beta domains of pVHL. EAF2 stabilizes pVHL protein as shown by stability and pulse-chase studies. EAF2 knockout mice show reduced pVHL levels in testes and MEFs and exhibit increased HIF-1alpha levels and activity, increased angiogenesis in Matrigel plug assays, and vascular system abnormalities consistent with a pVHL-dependent mechanism.","method":"Co-immunoprecipitation, in vitro binding assay, deletion mutagenesis, protein stability assay, pulse-chase study, Matrigel plug assay, EAF2 knockout mouse model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro binding plus co-IP with deletion mutagenesis, pulse-chase stability assay, and in vivo validation in knockout mouse; multiple orthogonal methods","pmids":["19258512"],"is_preprint":false},{"year":2009,"finding":"EAF2 co-localizes and co-immunoprecipitates with p53 in transfected cells. In a TSP-1 promoter luciferase reporter assay, p53 suppresses TSP-1 promoter activity, and co-transfection with EAF2 blocks this p53-mediated suppression. EAF2 knockout mice show downregulation of the anti-angiogenic protein thrombospondin-1 (TSP-1) in prostate and liver, and increased CD31-positive blood vessels in liver, suggesting EAF2 regulates TSP-1 expression by blocking p53 repression of the TSP-1 promoter.","method":"Co-immunoprecipitation, luciferase reporter assay, immunohistochemistry, EAF2 knockout mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, luciferase reporter, and in vivo KO validation; single lab with multiple orthogonal methods","pmids":["19826414"],"is_preprint":false},{"year":2009,"finding":"EAF1 and EAF2 (Eafs) maintain expression levels of wnt11 and wnt5 in zebrafish, acting upstream of noncanonical Wnt signaling to mediate convergence and extension movements and midline convergence of organ precursors. Eaf morpholino knockdown disrupts cell migration (shown by kaeda mRNA cell tracing) and wnt11/wnt5 mRNA rescue recovers convergence and extension defects. rhoA mRNA rescue is more effective than either wnt alone, consistent with Wnt11/Wnt5 converging on RhoA.","method":"Morpholino knockdown, mRNA rescue, in situ hybridization, kaeda mRNA cell tracing, genetic epistasis analysis in zebrafish","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — morpholino knockdown, mRNA rescue, cell tracing, and epistasis all in same study; multiple orthogonal methods establish pathway position","pmids":["19380582"],"is_preprint":false},{"year":2010,"finding":"EAF1 and EAF2 are upregulated by Wnt4 signaling, and both proteins directly bind the Wnt4 promoter (shown by chromatin immunoprecipitation) to suppress Wnt4 expression, establishing an auto-regulatory negative feedback loop between Wnt4 and the EAF family conserved between zebrafish and mammals.","method":"Chromatin immunoprecipitation, reporter assay, morpholino knockdown and mRNA rescue in zebrafish, RT-PCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, combined with in vivo zebrafish rescue experiments; single lab","pmids":["20161747"],"is_preprint":false},{"year":2011,"finding":"Combined loss of EAF2 and VHL heterozygosity cooperatively increases angiogenesis in mouse liver and prostate, with increased microvessel density and HIF-1alpha/VEGF staining. EAF2(-/-) VHL(+/-) mice show higher incidence of proliferative hepatic vascular lesions and prostatic intraepithelial neoplasia compared to either single mutant, demonstrating in vivo cooperation between EAF2 and VHL in angiogenic regulation.","method":"Mouse genetic cross (EAF2(-/-) x VHL(+/-)), immunohistochemistry, microvessel density quantification","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo compound knockout epistasis experiment with quantified angiogenic phenotypes; single lab","pmids":["21638067"],"is_preprint":false},{"year":2013,"finding":"EAF1 and EAF2 inhibit canonical Wnt/beta-catenin signaling in zebrafish and cultured cells. By immunoprecipitation, Eaf1 and Eaf2 bind to the Armadillo repeat region and C-terminus of beta-catenin, and also interact with c-Jun, Tcf, and Axin, forming a novel complex. The N-terminus of Eaf1/Eaf2 binds beta-catenin and exhibits dominant-negative activity; the C-terminus contains a suppression domain or recruits a repressor. Both termini must be intact for full suppressive activity. Loss- and gain-of-function assays in zebrafish confirm modulation of mesodermal and neural patterning.","method":"Morpholino knockdown, mRNA injection, immunoprecipitation, beta-catenin reporter assay, deletion mutagenesis in zebrafish and cultured cells","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, reporter assay, in vivo loss/gain-of-function, domain mutagenesis) establishing direct interaction and mechanism; single lab but comprehensive","pmids":["23364330"],"is_preprint":false},{"year":2013,"finding":"Concomitant loss of EAF2 and heterozygous loss of Pten synergistically promotes prostate cancer in mice (33% incidence), with elevated phospho-Akt, phospho-p44/42, increased microvessel density, and higher epithelial proliferation in intact and castrated EAF2(-/-)Pten(+/-) mice compared to single mutants. This demonstrates functional interaction between EAF2 and the PTEN/PI3K/Akt pathway in prostate carcinogenesis.","method":"Compound knockout mouse model (EAF2(-/-) x Pten(+/-)), immunohistochemistry, laser-capture microdissection with RT-PCR, proliferation analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo epistasis with compound knockout, multiple molecular readouts (p-Akt, p-MAPK, microvessel density, proliferation), validated in clinical specimens","pmids":["23708662"],"is_preprint":false},{"year":2013,"finding":"Pirin was identified as a binding partner of EAF2 by yeast two-hybrid screening and confirmed by co-immunoprecipitation in mammalian cells. Overexpressed Pirin decreases EAF2 protein levels in prostate cancer cell lines and blocks EAF2-mediated growth inhibition of LNCaP cells, establishing Pirin as a regulator of EAF2 protein stability and function.","method":"Yeast two-hybrid screening, co-immunoprecipitation, colony formation assay","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid confirmed by co-IP and functional assay; single lab with two orthogonal methods","pmids":["24272884"],"is_preprint":false},{"year":2014,"finding":"EAF2 is a hypoxia-response gene containing a hypoxia response element (HRE) in its promoter. HIF-1alpha (but not HIF-2alpha) induces EAF2 expression under hypoxia. EAF2 in turn binds and suppresses HIF-1alpha (but not HIF-2alpha) transactivation by disrupting p300/CBP recruitment to HIF-1alpha, independently of FIH-1 and Sirt1. EAF2 also protects cells against hypoxia-induced cell death and inhibits cellular glucose uptake under hypoxia, establishing a negative feedback loop between EAF2 and HIF-1alpha.","method":"HRE reporter assay, co-immunoprecipitation, luciferase transactivation assay, pVHL-null cell lines (RCC4 and 786-O), glucose uptake assay, cell viability assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assay, co-IP, pVHL-null cell lines as mechanistic controls, glucose uptake, viability assays), isoform specificity demonstrated; single lab but rigorous","pmids":["24421387"],"is_preprint":false},{"year":2015,"finding":"EAF2 co-immunoprecipitates with FOXA1 in human prostate cancer cells. EAF2 knockdown enhances endogenous FOXA1 protein levels, while GFP-EAF2 overexpression down-regulates FOXA1 protein. FOXA1 knockdown inhibits EAF2-knockdown-induced enhancement of AR target gene expression, cell proliferation, and migration in LNCaP cells, indicating that FOXA1 mediates EAF2 regulation of AR signaling, proliferation, and migration. The ortholog pha-4 (C. elegans FOXA1) was identified by RNAi screen in eaf-1 mutant worms as synergistically enhancing reduced fertility.","method":"Co-immunoprecipitation, protein stability assay, RNAi screen in C. elegans, RT-PCR, luciferase reporter assay, BrdU proliferation assay, transwell migration assay","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, protein stability, functional epistasis in two model systems (C. elegans and human cells), multiple cell-based assays; single lab","pmids":["25808853"],"is_preprint":false},{"year":2016,"finding":"EAF2 is selectively upregulated in germinal centre (GC) B cells and promotes their apoptosis both in vitro and in vivo. EAF2 deficiency results in enlarged GCs and elevated antibody production during T-dependent immune responses. EAF2-knockout mice develop severe collagen-induced arthritis with high autoantibody titers and spontaneously produce anti-dsDNA, rheumatoid factor, and anti-nuclear antibodies with age, demonstrating that EAF2-mediated apoptosis in GC B cells limits excessive humoral immune responses and maintains self-tolerance.","method":"EAF2 knockout mouse model, immunization assay, collagen-induced arthritis model, flow cytometry, apoptosis assay in vitro and in vivo","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with multiple defined immunological phenotypes and mechanistic readouts (GC size, antibody titers, autoantibodies, apoptosis), validated in two independent disease models","pmids":["26935903"],"is_preprint":false},{"year":2016,"finding":"EAF2 and EAF1 are required for the recruitment and retention of Ku70/Ku80 to DNA damage sites and play a functional role in nonhomologous end-joining (NHEJ) DNA repair. EAF2 knockdown sensitizes prostate cancer cells to DNA damage in a p53-independent manner, and EAF2 knockout mouse prostate is sensitized to gamma-irradiation. EAF2 knockdown blocks androgen-mediated repression of gamma-H2ax induction by doxorubicin, suggesting EAF2 mediates androgen protection against DNA damage via Ku70/Ku80.","method":"siRNA knockdown, EAF2 knockout mouse model, gamma-H2ax immunofluorescence, DNA damage sensitivity assay (doxorubicin, gamma-irradiation), NHEJ reporter assay, Ku70/Ku80 recruitment assay at DNA damage sites","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse and siRNA knockdown with defined molecular mechanism (Ku70/Ku80 recruitment), NHEJ functional assay, multiple cell lines and in vivo validation; single lab but multiple orthogonal methods","pmids":["27721405"],"is_preprint":false},{"year":2018,"finding":"Concurrent knockdown of EAF2 and p53 in prostate cancer cells activates STAT3 signaling (increased p-STAT3), and STAT3 knockdown abrogates the stimulation of cell proliferation caused by co-knockdown of EAF2 and p53. EAF2(-/-)p53(-/-) mouse prostate shows significantly increased p-STAT3 immunostaining, establishing that EAF2 and p53 co-regulate STAT3 activation in prostate cancer.","method":"RNA-seq, siRNA knockdown, immunohistochemistry in mouse prostate (Eaf2-/-p53-/- model), human prostate cancer specimen immunostaining, cell proliferation assay","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — compound KO mouse model with molecular validation (RNA-seq, IHC), epistasis via STAT3 knockdown rescue, and human specimen correlation; single lab","pmids":["29518696"],"is_preprint":false},{"year":2003,"finding":"Murine Eaf2 is preferentially expressed in the central nervous system, sensory and neuroendocrine organs during embryogenesis. In the developing lens, Eaf2 is absent from proliferating anterior lens epithelial cells but present in terminally differentiated primary lens fiber cells and non-proliferating lens fiber cells in the equatorial zone, suggesting a role in regulating lens cell differentiation and maturation.","method":"In situ hybridization during mouse embryogenesis, spatial expression analysis","journal":"Developmental dynamics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (in situ hybridization) establishing localization/expression without direct functional experiment","pmids":["14517999"],"is_preprint":false},{"year":2011,"finding":"RNAi-mediated silencing of EAF2 in HCT-116 colon cancer cells modulates cellular response to both simvastatin and lovastatin, as validated by functional RNAi experiments following bioinformatic identification of EAF2 from NCI60 panel data.","method":"Bioinformatic analysis of NCI60 SNP data, RNAi functional validation in HCT-116 cells","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single RNAi validation experiment with phenotypic readout only (drug response), no pathway mechanism established","pmids":["21483694"],"is_preprint":false}],"current_model":"EAF2 is an androgen-regulated tumor suppressor that functions as a component of the ELL RNA polymerase II transcription elongation complex, where ELL binding controls EAF2 nuclear localization, stability, and transactivation; EAF2 suppresses tumorigenesis through multiple mechanisms including: binding and stabilizing pVHL to restrict HIF-1alpha activity and angiogenesis, directly binding beta-catenin and its co-factors to inhibit canonical Wnt signaling, forming a negative feedback loop with Wnt4, disrupting p300 recruitment to HIF-1alpha, co-regulating p53 and STAT3 signaling, promoting Ku70/Ku80-dependent nonhomologous end-joining DNA repair, and inducing apoptosis in germinal centre B cells to suppress autoimmunity; in vivo knockout models demonstrate EAF2 loss leads to multi-organ tumorigenesis, excessive humoral immune responses, and synergistic carcinogenesis with PTEN loss."},"narrative":{"mechanistic_narrative":"EAF2 is an androgen-regulated tumor suppressor that originates as a component of the ELL RNA polymerase II transcription elongation machinery, binding the amino-terminal domain of ELL through a region (residues 68–113) that also carries its growth-suppressive and apoptotic activity [PMID:12446457, PMID:17044034]. ELL binding governs EAF2 nuclear speckle formation, protein stability, and transactivation, coupling the elongation partnership to EAF2 function [PMID:16114057]. Its tumor-suppressive role is established in vivo: germline knockout produces multi-organ tumorigenesis including lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma, and prostatic intraepithelial neoplasia, alongside cell-size and proliferation defects [PMID:17873910], and EAF2 loss cooperates with Pten heterozygosity to drive prostate cancer through PI3K/Akt activation [PMID:23708662]. EAF2 restrains angiogenesis through two convergent mechanisms: it binds and stabilizes pVHL to limit HIF-1alpha accumulation and activity [PMID:19258512, PMID:21638067], and it directly binds and selectively suppresses HIF-1alpha transactivation by disrupting p300/CBP recruitment within a hypoxia-driven negative feedback loop [PMID:24421387]. EAF2 inhibits canonical Wnt/beta-catenin signaling by binding the Armadillo region and C-terminus of beta-catenin together with c-Jun, Tcf, and Axin, while participating in an autoregulatory feedback loop with noncanonical Wnt4/Wnt11/Wnt5 signaling that controls morphogenetic movements and patterning [PMID:23364330, PMID:20161747, PMID:19380582]. Additional tumor-suppressive and homeostatic outputs include co-regulation of p53-dependent thrombospondin-1 expression and STAT3 activation [PMID:19826414, PMID:29518696], promotion of Ku70/Ku80-dependent nonhomologous end-joining repair [PMID:27721405], modulation of androgen receptor signaling via FOXA1 [PMID:25808853], and induction of germinal-centre B-cell apoptosis to limit autoimmunity [PMID:26935903].","teleology":[{"year":2002,"claim":"Established EAF2's molecular identity by showing it is a dedicated partner of the ELL elongation factor with its own transcriptional activation domain, placing it in the RNA Pol II elongation machinery.","evidence":"Reciprocal Co-IP from multiple cell lines, confocal co-localization, deletion mapping, and transactivation assays","pmids":["12446457"],"confidence":"High","gaps":["Did not establish endogenous target genes regulated by the EAF2-ELL complex","Physiological role beyond elongation partnership unaddressed"]},{"year":2003,"claim":"Mapped EAF2's developmental expression to neural and sensory tissues and differentiated lens fibers, hinting at a role in cell differentiation.","evidence":"In situ hybridization across mouse embryogenesis","pmids":["14517999"],"confidence":"Low","gaps":["Expression-only data with no functional perturbation","No mechanism linking EAF2 to lens differentiation"]},{"year":2005,"claim":"Positioned EAF2 downstream of noncanonical Wnt-4 signaling in eye development, linking its elongation-factor activity to a developmental pathway.","evidence":"Morpholino knockdown, mRNA rescue, and in situ hybridization in Xenopus","pmids":["15775981"],"confidence":"High","gaps":["Direct target genes of EAF2 in eye specification not defined","Mammalian relevance of the Wnt4-EAF2 axis not yet tested"]},{"year":2006,"claim":"Showed that ELL binding is not just structural but controls EAF2 localization, stability, and activity, establishing the partnership as functionally regulatory.","evidence":"Co-transfection, Co-IP, protein stability and transactivation assays in prostate cells","pmids":["16114057"],"confidence":"Medium","gaps":["Mechanism of ELL-dependent stabilization (e.g., protection from degradation) not resolved","Single-lab data"]},{"year":2007,"claim":"Defined a minimal EAF2 region required for both ELL binding and tumor suppression, and demonstrated EAF2 is a bona fide tumor suppressor in vivo.","evidence":"Deletion mutants with colony formation/apoptosis assays; multi-organ tumor phenotyping in EAF2 knockout mice","pmids":["17044034","17873910"],"confidence":"High","gaps":["Molecular drivers of each tissue-specific tumor type not dissected","Link between elongation activity and tumor suppression unresolved"]},{"year":2009,"claim":"Identified pVHL stabilization and p53/TSP-1 regulation as anti-angiogenic mechanisms, mechanistically connecting EAF2 loss to increased HIF-1alpha and vascular abnormalities.","evidence":"Co-IP, in vitro binding, pulse-chase stability, Matrigel plug assays in knockout mice; luciferase reporter and IHC for p53/TSP-1","pmids":["19258512","19826414"],"confidence":"High","gaps":["How EAF2 stabilizes pVHL biochemically not defined","Relative contribution of pVHL vs p53 routes to angiogenesis unclear"]},{"year":2009,"claim":"Placed EAF family upstream of noncanonical Wnt (wnt11/wnt5) signaling controlling convergence-extension, expanding EAF2's role in morphogenesis.","evidence":"Morpholino knockdown, mRNA rescue, cell tracing, and epistasis in zebrafish","pmids":["19380582"],"confidence":"High","gaps":["Direct transcriptional targets among wnt genes not shown in this study","Redundancy between EAF1 and EAF2 not separated"]},{"year":2010,"claim":"Demonstrated direct EAF binding to the Wnt4 promoter, establishing an autoregulatory Wnt4-EAF negative feedback loop conserved across species.","evidence":"ChIP, reporter assays, and zebrafish knockdown/rescue","pmids":["20161747"],"confidence":"Medium","gaps":["Co-factors mediating promoter repression not identified","Single-lab data"]},{"year":2011,"claim":"Provided in vivo genetic evidence that EAF2 and VHL cooperate to restrain angiogenesis, and connected EAF2 to drug-response phenotypes.","evidence":"EAF2(-/-) x VHL(+/-) compound mouse cross with microvessel quantification; separate RNAi statin-response screen in HCT-116","pmids":["21638067","21483694"],"confidence":"Medium","gaps":["Statin-response link is phenotype-only with no mechanism (Low confidence)","Tissue specificity of EAF2-VHL cooperation not explained"]},{"year":2013,"claim":"Resolved EAF2's mechanism of canonical Wnt inhibition and its synergy with PTEN loss in carcinogenesis, integrating Wnt and PI3K/Akt axes into its tumor-suppressive program.","evidence":"Co-IP, beta-catenin reporter, domain mutagenesis in zebrafish/cells; EAF2(-/-) x Pten(+/-) compound mouse model with IHC and proliferation readouts","pmids":["23364330","23708662"],"confidence":"High","gaps":["Whether beta-catenin binding requires the ELL partnership not tested","C-terminal repressor identity in the beta-catenin complex unknown"]},{"year":2013,"claim":"Identified Pirin as a negative regulator of EAF2 stability, revealing a route by which EAF2 tumor-suppressive function can be downmodulated.","evidence":"Yeast two-hybrid screen, Co-IP, and colony formation rescue","pmids":["24272884"],"confidence":"Medium","gaps":["Mechanism by which Pirin destabilizes EAF2 not defined","In vivo relevance not tested"]},{"year":2014,"claim":"Established a direct EAF2-HIF-1alpha negative feedback loop independent of pVHL, showing isoform-specific suppression of HIF-1alpha via blockade of p300/CBP recruitment.","evidence":"HRE reporter, Co-IP, transactivation assays in pVHL-null cells, glucose uptake and viability assays","pmids":["24421387"],"confidence":"High","gaps":["Structural basis of HIF-1alpha vs HIF-2alpha selectivity unresolved","Interplay between the pVHL-dependent and pVHL-independent HIF routes not integrated"]},{"year":2015,"claim":"Connected EAF2 to androgen receptor signaling by showing it suppresses FOXA1, which mediates EAF2 control of AR target genes, proliferation, and migration.","evidence":"Co-IP, protein stability assays, C. elegans RNAi epistasis, and cell-based proliferation/migration assays","pmids":["25808853"],"confidence":"Medium","gaps":["Mechanism of FOXA1 downregulation by EAF2 not defined","Single-lab data"]},{"year":2016,"claim":"Defined EAF2's DNA-repair and immune-homeostasis functions, showing it promotes Ku70/Ku80-dependent NHEJ and drives germinal-centre B-cell apoptosis to prevent autoimmunity.","evidence":"siRNA and knockout mouse models with gamma-H2ax IF, NHEJ reporter, Ku recruitment assays; immunization and collagen-induced arthritis models with flow cytometry and apoptosis assays","pmids":["27721405","26935903"],"confidence":"High","gaps":["How EAF2 recruits/retains Ku70/Ku80 mechanistically is unresolved","Trigger of EAF2 upregulation in GC B cells unknown"]},{"year":2018,"claim":"Showed that EAF2 and p53 jointly restrain STAT3 activation, adding an oncogenic-signaling axis to EAF2's tumor-suppressive network in prostate cancer.","evidence":"RNA-seq, siRNA knockdown with STAT3 rescue, IHC in EAF2(-/-)p53(-/-) mouse prostate and human specimens","pmids":["29518696"],"confidence":"Medium","gaps":["Direct mechanism linking EAF2/p53 loss to STAT3 phosphorylation not defined","Single-lab data"]},{"year":null,"claim":"How EAF2's core RNA Pol II elongation activity mechanistically unifies its diverse partner interactions (pVHL, HIF-1alpha, beta-catenin, Ku70/80, FOXA1) into a single tumor-suppressive program remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of EAF2 bound to its multiple partners","Whether transcriptional elongation activity is required for each non-transcriptional function untested","No unified picture of which interactions are direct versus complex-mediated in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,13]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,13,10]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[16]}],"localization":[{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[0,2]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,5]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,13,17]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[15]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,7]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[13]}],"complexes":["ELL elongation complex","beta-catenin/c-Jun/Tcf/Axin complex"],"partners":["ELL","VHL","HIF1A","CTNNB1","TP53","FOXA1","PIR","XRCC6"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96CJ1","full_name":"ELL-associated factor 2","aliases":["Testosterone-regulated apoptosis inducer and tumor suppressor protein"],"length_aa":260,"mass_kda":28.8,"function":"Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo","subcellular_location":"Nucleus speckle","url":"https://www.uniprot.org/uniprotkb/Q96CJ1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EAF2","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EAF2","total_profiled":1310},"omim":[{"mim_id":"608315","title":"ELL-ASSOCIATED FACTOR 1; EAF1","url":"https://www.omim.org/entry/608315"},{"mim_id":"607659","title":"ELL-ASSOCIATED FACTOR 2; EAF2","url":"https://www.omim.org/entry/607659"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":67.8},{"tissue":"lymphoid tissue","ntpm":50.0}],"url":"https://www.proteinatlas.org/search/EAF2"},"hgnc":{"alias_symbol":["BM040","TRAITS","U19"],"prev_symbol":[]},"alphafold":{"accession":"Q96CJ1","domains":[{"cath_id":"-","chopping":"16-110","consensus_level":"high","plddt":95.0615,"start":16,"end":110}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96CJ1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96CJ1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96CJ1-F1-predicted_aligned_error_v6.png","plddt_mean":70.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EAF2","jax_strain_url":"https://www.jax.org/strain/search?query=EAF2"},"sequence":{"accession":"Q96CJ1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96CJ1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96CJ1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96CJ1"}},"corpus_meta":[{"pmid":"28622505","id":"PMC_28622505","title":"An Expanded View of Complex Traits: From Polygenic to Omnigenic.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28622505","citation_count":1927,"is_preprint":false},{"pmid":"11700286","id":"PMC_11700286","title":"The genetic architecture of quantitative traits.","date":"2001","source":"Annual review of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11700286","citation_count":685,"is_preprint":false},{"pmid":"33122355","id":"PMC_33122355","title":"Physical traits of cancer.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33122355","citation_count":624,"is_preprint":false},{"pmid":"12493905","id":"PMC_12493905","title":"Finding genes that underlie complex traits.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12493905","citation_count":578,"is_preprint":false},{"pmid":"32888494","id":"PMC_32888494","title":"The Polygenic and Monogenic Basis of Blood Traits and Diseases.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32888494","citation_count":552,"is_preprint":false},{"pmid":"24296534","id":"PMC_24296534","title":"Systems genetics approaches to understand complex traits.","date":"2013","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24296534","citation_count":458,"is_preprint":false},{"pmid":"24135279","id":"PMC_24135279","title":"Origins of metastatic traits.","date":"2013","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24135279","citation_count":436,"is_preprint":false},{"pmid":"25580769","id":"PMC_25580769","title":"Flood adaptive traits and processes: an overview.","date":"2015","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/25580769","citation_count":413,"is_preprint":false},{"pmid":"22077970","id":"PMC_22077970","title":"Abundant pleiotropy in human complex diseases and traits.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22077970","citation_count":399,"is_preprint":false},{"pmid":"21935886","id":"PMC_21935886","title":"Posttranscriptional regulation of cancer traits by HuR.","date":"2010","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/21935886","citation_count":352,"is_preprint":false},{"pmid":"10700173","id":"PMC_10700173","title":"Analysing complex genetic traits with chromosome substitution strains.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10700173","citation_count":318,"is_preprint":false},{"pmid":"32694620","id":"PMC_32694620","title":"Unique and common traits in mycorrhizal symbioses.","date":"2020","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32694620","citation_count":284,"is_preprint":false},{"pmid":"25971588","id":"PMC_25971588","title":"Fungal traits that drive ecosystem dynamics on land.","date":"2015","source":"Microbiology and molecular biology reviews : MMBR","url":"https://pubmed.ncbi.nlm.nih.gov/25971588","citation_count":260,"is_preprint":false},{"pmid":"20332804","id":"PMC_20332804","title":"What traits are carried on mobile genetic elements, and why?","date":"2010","source":"Heredity","url":"https://pubmed.ncbi.nlm.nih.gov/20332804","citation_count":238,"is_preprint":false},{"pmid":"16048784","id":"PMC_16048784","title":"Theoretical models of selection and mutation on quantitative traits.","date":"2005","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16048784","citation_count":233,"is_preprint":false},{"pmid":"30415840","id":"PMC_30415840","title":"Identity Noise and Adipogenic Traits Characterize Dermal Fibroblast Aging.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/30415840","citation_count":188,"is_preprint":false},{"pmid":"15592805","id":"PMC_15592805","title":"Regulatory polymorphisms underlying complex disease traits.","date":"2004","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/15592805","citation_count":167,"is_preprint":false},{"pmid":"30257690","id":"PMC_30257690","title":"Epigenetic prediction of complex traits and death.","date":"2018","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/30257690","citation_count":160,"is_preprint":false},{"pmid":"26157023","id":"PMC_26157023","title":"Strategies for fine-mapping complex traits.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26157023","citation_count":157,"is_preprint":false},{"pmid":"25387784","id":"PMC_25387784","title":"Invited review: overview of new traits and phenotyping strategies in dairy cattle with a focus on functional traits.","date":"2014","source":"Animal : an international journal of animal bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/25387784","citation_count":148,"is_preprint":false},{"pmid":"24667992","id":"PMC_24667992","title":"Brassinosteroid-mediated regulation of agronomic traits in rice.","date":"2014","source":"Plant cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24667992","citation_count":144,"is_preprint":false},{"pmid":"24101678","id":"PMC_24101678","title":"Autism traits in the RASopathies.","date":"2013","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24101678","citation_count":136,"is_preprint":false},{"pmid":"32300964","id":"PMC_32300964","title":"Regulation of senescence traits by MAPKs.","date":"2020","source":"GeroScience","url":"https://pubmed.ncbi.nlm.nih.gov/32300964","citation_count":123,"is_preprint":false},{"pmid":"26371406","id":"PMC_26371406","title":"Predicting microbial traits with phylogenies.","date":"2015","source":"The ISME journal","url":"https://pubmed.ncbi.nlm.nih.gov/26371406","citation_count":121,"is_preprint":false},{"pmid":"25084048","id":"PMC_25084048","title":"Heterogeneity of dopamine neuron activity across traits and states.","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25084048","citation_count":117,"is_preprint":false},{"pmid":"10689800","id":"PMC_10689800","title":"Clines in polygenic traits.","date":"1999","source":"Genetical research","url":"https://pubmed.ncbi.nlm.nih.gov/10689800","citation_count":116,"is_preprint":false},{"pmid":"25389175","id":"PMC_25389175","title":"Mucins suppress virulence traits of Candida albicans.","date":"2014","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/25389175","citation_count":112,"is_preprint":false},{"pmid":"37561875","id":"PMC_37561875","title":"DNA methylation networks underlying mammalian traits.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37561875","citation_count":97,"is_preprint":false},{"pmid":"15775981","id":"PMC_15775981","title":"Noncanonical Wnt-4 signaling and EAF2 are required for eye development in Xenopus laevis.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15775981","citation_count":83,"is_preprint":false},{"pmid":"28880275","id":"PMC_28880275","title":"LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28880275","citation_count":80,"is_preprint":false},{"pmid":"10689810","id":"PMC_10689810","title":"Properties of spontaneous mutations affecting quantitative traits.","date":"1999","source":"Genetical research","url":"https://pubmed.ncbi.nlm.nih.gov/10689810","citation_count":79,"is_preprint":false},{"pmid":"12446457","id":"PMC_12446457","title":"ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12446457","citation_count":72,"is_preprint":false},{"pmid":"16086848","id":"PMC_16086848","title":"Evolution of selenium utilization traits.","date":"2005","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/16086848","citation_count":72,"is_preprint":false},{"pmid":"24443922","id":"PMC_24443922","title":"On the fate of sexual traits under asexuality.","date":"2014","source":"Biological reviews of the Cambridge Philosophical Society","url":"https://pubmed.ncbi.nlm.nih.gov/24443922","citation_count":71,"is_preprint":false},{"pmid":"34030967","id":"PMC_34030967","title":"Emerging Patterns of Microbial Functional Traits.","date":"2021","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34030967","citation_count":68,"is_preprint":false},{"pmid":"28475861","id":"PMC_28475861","title":"Widespread Allelic Heterogeneity in Complex Traits.","date":"2017","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28475861","citation_count":67,"is_preprint":false},{"pmid":"17873910","id":"PMC_17873910","title":"U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17873910","citation_count":59,"is_preprint":false},{"pmid":"35676261","id":"PMC_35676261","title":"Global relationships in tree functional traits.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35676261","citation_count":59,"is_preprint":false},{"pmid":"38632397","id":"PMC_38632397","title":"Hybrid speciation driven by multilocus introgression of ecological traits.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38632397","citation_count":55,"is_preprint":false},{"pmid":"22976472","id":"PMC_22976472","title":"Genetic and epigenetic contribution to complex traits.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22976472","citation_count":51,"is_preprint":false},{"pmid":"23364330","id":"PMC_23364330","title":"Eaf1 and Eaf2 negatively regulate canonical Wnt/β-catenin signaling.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23364330","citation_count":50,"is_preprint":false},{"pmid":"32796036","id":"PMC_32796036","title":"The ubiquitin system affects agronomic plant traits.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32796036","citation_count":46,"is_preprint":false},{"pmid":"28286704","id":"PMC_28286704","title":"Genetics of Lipid and Lipoprotein Disorders and Traits.","date":"2016","source":"Current genetic medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28286704","citation_count":45,"is_preprint":false},{"pmid":"19380582","id":"PMC_19380582","title":"Zebrafish eaf1 and eaf2/u19 mediate effective convergence and extension movements through the maintenance of wnt11 and wnt5 expression.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19380582","citation_count":44,"is_preprint":false},{"pmid":"31961865","id":"PMC_31961865","title":"Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31961865","citation_count":44,"is_preprint":false},{"pmid":"25772476","id":"PMC_25772476","title":"Mapping complex traits as a dynamic system.","date":"2015","source":"Physics of life reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25772476","citation_count":43,"is_preprint":false},{"pmid":"35560157","id":"PMC_35560157","title":"Shared genetic loci between depression and cardiometabolic traits.","date":"2022","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35560157","citation_count":41,"is_preprint":false},{"pmid":"37066995","id":"PMC_37066995","title":"GmJAZ3 interacts with GmRR18a and GmMYC2a to regulate seed traits in soybean.","date":"2023","source":"Journal of integrative plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/37066995","citation_count":41,"is_preprint":false},{"pmid":"25444161","id":"PMC_25444161","title":"Genetics of complex traits in psychiatry.","date":"2014","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25444161","citation_count":40,"is_preprint":false},{"pmid":"31998249","id":"PMC_31998249","title":"Fungal Traits Important for Soil Aggregation.","date":"2020","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31998249","citation_count":40,"is_preprint":false},{"pmid":"24421387","id":"PMC_24421387","title":"EAF2 suppresses hypoxia-induced factor 1α transcriptional activity by disrupting its interaction with coactivator CBP/p300.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24421387","citation_count":37,"is_preprint":false},{"pmid":"27895608","id":"PMC_27895608","title":"Genetic Consideration of Schizotypal Traits: A Review.","date":"2016","source":"Frontiers in psychology","url":"https://pubmed.ncbi.nlm.nih.gov/27895608","citation_count":37,"is_preprint":false},{"pmid":"19826414","id":"PMC_19826414","title":"Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19826414","citation_count":36,"is_preprint":false},{"pmid":"22231114","id":"PMC_22231114","title":"The unexpected traits associated with core promoter elements.","date":"2011","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/22231114","citation_count":35,"is_preprint":false},{"pmid":"36928026","id":"PMC_36928026","title":"Hyperactive nanobacteria with host-dependent traits pervade Omnitrophota.","date":"2023","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36928026","citation_count":33,"is_preprint":false},{"pmid":"34240182","id":"PMC_34240182","title":"Global Genetic Heterogeneity in Adaptive Traits.","date":"2021","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/34240182","citation_count":33,"is_preprint":false},{"pmid":"36292733","id":"PMC_36292733","title":"Runs of Homozygosity Revealed Reproductive Traits of Hu Sheep.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36292733","citation_count":32,"is_preprint":false},{"pmid":"26935903","id":"PMC_26935903","title":"EAF2 mediates germinal centre B-cell apoptosis to suppress excessive immune responses and prevent autoimmunity.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26935903","citation_count":31,"is_preprint":false},{"pmid":"33562333","id":"PMC_33562333","title":"Metabolomics Intervention Towards Better Understanding of Plant Traits.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33562333","citation_count":31,"is_preprint":false},{"pmid":"14732447","id":"PMC_14732447","title":"Evolution of developmental traits.","date":"2004","source":"Current opinion in plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/14732447","citation_count":31,"is_preprint":false},{"pmid":"19258512","id":"PMC_19258512","title":"U19/Eaf2 binds to and stabilizes von hippel-lindau protein.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19258512","citation_count":30,"is_preprint":false},{"pmid":"28386301","id":"PMC_28386301","title":"New traits in crops produced by genome editing techniques based on deletions.","date":"2017","source":"Plant biotechnology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28386301","citation_count":28,"is_preprint":false},{"pmid":"36629415","id":"PMC_36629415","title":"Plasmid-Encoded Traits Vary across Environments.","date":"2023","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/36629415","citation_count":27,"is_preprint":false},{"pmid":"30969020","id":"PMC_30969020","title":"Ultrastructural traits of apoptosis.","date":"2019","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/30969020","citation_count":27,"is_preprint":false},{"pmid":"34874068","id":"PMC_34874068","title":"Properties of phenotypic plasticity in discrete threshold traits.","date":"2021","source":"Evolution; international journal of organic evolution","url":"https://pubmed.ncbi.nlm.nih.gov/34874068","citation_count":27,"is_preprint":false},{"pmid":"19620689","id":"PMC_19620689","title":"Relationships between reproductive traits of heifers and cows and yield traits for Holsteins in Japan.","date":"2009","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/19620689","citation_count":27,"is_preprint":false},{"pmid":"23708662","id":"PMC_23708662","title":"Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23708662","citation_count":26,"is_preprint":false},{"pmid":"23325049","id":"PMC_23325049","title":"Modulation of cancer traits by tumor suppressor microRNAs.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23325049","citation_count":26,"is_preprint":false},{"pmid":"25808853","id":"PMC_25808853","title":"FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.","date":"2015","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/25808853","citation_count":25,"is_preprint":false},{"pmid":"32509589","id":"PMC_32509589","title":"Metabolic Traits in Cutaneous Melanoma.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32509589","citation_count":25,"is_preprint":false},{"pmid":"31300195","id":"PMC_31300195","title":"Plant Networks as Traits and Hypotheses: Moving Beyond Description.","date":"2019","source":"Trends in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/31300195","citation_count":25,"is_preprint":false},{"pmid":"27721405","id":"PMC_27721405","title":"EAF2 regulates DNA repair through Ku70/Ku80 in the prostate.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27721405","citation_count":24,"is_preprint":false},{"pmid":"34481004","id":"PMC_34481004","title":"Expression of ovine CTNNA3 and CAP2 genes and their association with growth traits.","date":"2021","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/34481004","citation_count":24,"is_preprint":false},{"pmid":"33798444","id":"PMC_33798444","title":"Association of structural variation with cardiometabolic traits in Finns.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33798444","citation_count":24,"is_preprint":false},{"pmid":"38106437","id":"PMC_38106437","title":"Regulation of seed traits in soybean.","date":"2023","source":"aBIOTECH","url":"https://pubmed.ncbi.nlm.nih.gov/38106437","citation_count":23,"is_preprint":false},{"pmid":"21638067","id":"PMC_21638067","title":"EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.","date":"2011","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21638067","citation_count":22,"is_preprint":false},{"pmid":"24385047","id":"PMC_24385047","title":"SLC6A4 polymorphism, population genetics, and psychiatric traits.","date":"2014","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24385047","citation_count":22,"is_preprint":false},{"pmid":"6371078","id":"PMC_6371078","title":"Traits for sire selection related to udder health and management.","date":"1984","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/6371078","citation_count":22,"is_preprint":false},{"pmid":"14517999","id":"PMC_14517999","title":"Expression of murine ELL-associated factor 2 (Eaf2) is developmentally regulated.","date":"2003","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/14517999","citation_count":21,"is_preprint":false},{"pmid":"25403527","id":"PMC_25403527","title":"Epistasis for quantitative traits in Drosophila.","date":"2015","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25403527","citation_count":21,"is_preprint":false},{"pmid":"37309422","id":"PMC_37309422","title":"Improving architectural traits of maize inflorescences.","date":"2021","source":"Molecular breeding : new strategies in plant improvement","url":"https://pubmed.ncbi.nlm.nih.gov/37309422","citation_count":21,"is_preprint":false},{"pmid":"29518696","id":"PMC_29518696","title":"EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29518696","citation_count":20,"is_preprint":false},{"pmid":"32220486","id":"PMC_32220486","title":"Genetic variants in MYF5 affected growth traits and beef quality traits in Chinese Qinchuan cattle.","date":"2020","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/32220486","citation_count":20,"is_preprint":false},{"pmid":"35347380","id":"PMC_35347380","title":"Pregnancy outcomes among women affected with thalassemia traits.","date":"2022","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/35347380","citation_count":19,"is_preprint":false},{"pmid":"20161747","id":"PMC_20161747","title":"Negative feedback regulation of Wnt4 signaling by EAF1 and EAF2/U19.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20161747","citation_count":18,"is_preprint":false},{"pmid":"23050961","id":"PMC_23050961","title":"Genomics of complex traits.","date":"2012","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23050961","citation_count":18,"is_preprint":false},{"pmid":"18507792","id":"PMC_18507792","title":"Towards molecular breeding of reproductive traits in cereal crops.","date":"2008","source":"Plant biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/18507792","citation_count":18,"is_preprint":false},{"pmid":"16114057","id":"PMC_16114057","title":"ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.","date":"2006","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/16114057","citation_count":18,"is_preprint":false},{"pmid":"36611708","id":"PMC_36611708","title":"Estimation of Genetic Parameters for Conformation Traits and Milk Production Traits in Chinese Holsteins.","date":"2022","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/36611708","citation_count":18,"is_preprint":false},{"pmid":"29058037","id":"PMC_29058037","title":"Epigenetic regulation of agronomical traits in Brassicaceae.","date":"2017","source":"Plant cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29058037","citation_count":17,"is_preprint":false},{"pmid":"37138640","id":"PMC_37138640","title":"Variation in Sphingomonas traits across habitats and phylogenetic clades.","date":"2023","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/37138640","citation_count":17,"is_preprint":false},{"pmid":"37041326","id":"PMC_37041326","title":"Thermophilic Dehalococcoidia with unusual traits shed light on an unexpected past.","date":"2023","source":"The ISME journal","url":"https://pubmed.ncbi.nlm.nih.gov/37041326","citation_count":17,"is_preprint":false},{"pmid":"31861203","id":"PMC_31861203","title":"Expression of Behavioural Traits in Goldendoodles and Labradoodles.","date":"2019","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/31861203","citation_count":17,"is_preprint":false},{"pmid":"24272884","id":"PMC_24272884","title":"Pirin down-regulates the EAF2/U19 protein and alleviates its growth inhibition in prostate cancer cells.","date":"2013","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/24272884","citation_count":16,"is_preprint":false},{"pmid":"21332828","id":"PMC_21332828","title":"Male reproductive traits and their relationship to reproductive traits in their female progeny: a systematic review.","date":"2011","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/21332828","citation_count":16,"is_preprint":false},{"pmid":"35214823","id":"PMC_35214823","title":"Exploring Breakthroughs in Three Traits Belonging to Seed Life.","date":"2022","source":"Plants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35214823","citation_count":15,"is_preprint":false},{"pmid":"33049683","id":"PMC_33049683","title":"Nanog promotes stem-like traits of glioblastoma cells.","date":"2021","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/33049683","citation_count":15,"is_preprint":false},{"pmid":"21483694","id":"PMC_21483694","title":"NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21483694","citation_count":15,"is_preprint":false},{"pmid":"36046583","id":"PMC_36046583","title":"Epigenetics and its role in effecting agronomical traits.","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/36046583","citation_count":14,"is_preprint":false},{"pmid":"17044034","id":"PMC_17044034","title":"Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain.","date":"2007","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/17044034","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42019,"output_tokens":5853,"usd":0.106926,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14463,"output_tokens":4947,"usd":0.097995,"stage2_stop_reason":"end_turn"},"total_usd":0.204921,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"EAF2 (ELL-associated factor 2) physically interacts with ELL RNA polymerase II elongation factor; endogenous EAF2 and ELL co-immunoprecipitate from multiple cell lines and co-localize in a nuclear speckled pattern by confocal microscopy. EAF2 binds to the amino-terminal domain of ELL (distinct from the carboxy-terminal domain that binds EAF1). EAF2 contains a transcriptional activation domain in its serine/aspartate/glutamate-rich region. MLL-ELL fusion protein retains the EAF1 interaction domain but not the EAF2 interaction domain.\",\n      \"method\": \"Co-immunoprecipitation from multiple cell lines, confocal microscopy, deletion mutagenesis, transcriptional activation assay, retroviral bone marrow transduction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reciprocal Co-IP from multiple cell lines, mutagenesis mapping of interaction domain, orthogonal localization data, transcriptional activation assay; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12446457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"EAF2 is a downstream target gene of noncanonical (beta-catenin-independent) Wnt-4 signaling in Xenopus laevis. EAF2 is specifically expressed in the developing eye and its expression depends on Wnt-4 function. Loss-of-function of EAF2 causes loss of eyes, and EAF2 overexpression can rescue loss of Wnt-4 function. In neuralized animal caps, EAF2 regulates expression of the eye-specific transcription factor Rx, consistent with a role as an RNA polymerase II elongation factor.\",\n      \"method\": \"Morpholino knockdown, mRNA rescue injections, in situ hybridization, Xenopus laevis loss-of-function assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with morpholino and gain-of-function rescue in Xenopus, multiple orthogonal methods establishing pathway position downstream of noncanonical Wnt-4\",\n      \"pmids\": [\"15775981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ELL binding is required for nuclear speckle formation of EAF2, stabilizes EAF2 protein, and enhances its transactivation activity. ELL binding therefore controls EAF2 intracellular localization, stability, and transcriptional function.\",\n      \"method\": \"Co-transfection, co-immunoprecipitation, protein stability assay, transactivation assay\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, stability assay, and transactivation assay in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16114057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The region of EAF2 (amino acids 68–113) is necessary and sufficient for both ELL binding and for induction of apoptosis and growth suppression in prostate cancer cells. Co-expression of EAF2 and ELL leads to significantly increased cell death and growth suppression, indicating that ELL interaction is essential for EAF2's apoptotic and tumor-suppressive functions.\",\n      \"method\": \"Transfection of deletion mutants, colony formation assay, co-immunoprecipitation\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis mapping of functional domain with co-IP validation and apoptosis assay, single lab\",\n      \"pmids\": [\"17044034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Homozygous or heterozygous knockout of EAF2 in mice results in high rates of lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma, and prostatic intraepithelial neoplasia. EAF2 deficiency in the mouse prostate enhances cell proliferation and increases epithelial cell size, and the knockout mice also exhibit cardiac cell hypertrophy, establishing EAF2 as a tumor suppressor with roles in growth suppression and cell size control in multiple tissues.\",\n      \"method\": \"Murine knockout model (homozygous and heterozygous), histopathology, cell proliferation analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout model with defined multi-organ tumor phenotype, replicated across multiple tissue types in same study\",\n      \"pmids\": [\"17873910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EAF2 physically binds to pVHL (von Hippel-Lindau protein) via its NH2-terminus (EAF2) and both alpha and beta domains of pVHL. EAF2 stabilizes pVHL protein as shown by stability and pulse-chase studies. EAF2 knockout mice show reduced pVHL levels in testes and MEFs and exhibit increased HIF-1alpha levels and activity, increased angiogenesis in Matrigel plug assays, and vascular system abnormalities consistent with a pVHL-dependent mechanism.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, deletion mutagenesis, protein stability assay, pulse-chase study, Matrigel plug assay, EAF2 knockout mouse model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro binding plus co-IP with deletion mutagenesis, pulse-chase stability assay, and in vivo validation in knockout mouse; multiple orthogonal methods\",\n      \"pmids\": [\"19258512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EAF2 co-localizes and co-immunoprecipitates with p53 in transfected cells. In a TSP-1 promoter luciferase reporter assay, p53 suppresses TSP-1 promoter activity, and co-transfection with EAF2 blocks this p53-mediated suppression. EAF2 knockout mice show downregulation of the anti-angiogenic protein thrombospondin-1 (TSP-1) in prostate and liver, and increased CD31-positive blood vessels in liver, suggesting EAF2 regulates TSP-1 expression by blocking p53 repression of the TSP-1 promoter.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, immunohistochemistry, EAF2 knockout mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, luciferase reporter, and in vivo KO validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19826414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EAF1 and EAF2 (Eafs) maintain expression levels of wnt11 and wnt5 in zebrafish, acting upstream of noncanonical Wnt signaling to mediate convergence and extension movements and midline convergence of organ precursors. Eaf morpholino knockdown disrupts cell migration (shown by kaeda mRNA cell tracing) and wnt11/wnt5 mRNA rescue recovers convergence and extension defects. rhoA mRNA rescue is more effective than either wnt alone, consistent with Wnt11/Wnt5 converging on RhoA.\",\n      \"method\": \"Morpholino knockdown, mRNA rescue, in situ hybridization, kaeda mRNA cell tracing, genetic epistasis analysis in zebrafish\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — morpholino knockdown, mRNA rescue, cell tracing, and epistasis all in same study; multiple orthogonal methods establish pathway position\",\n      \"pmids\": [\"19380582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"EAF1 and EAF2 are upregulated by Wnt4 signaling, and both proteins directly bind the Wnt4 promoter (shown by chromatin immunoprecipitation) to suppress Wnt4 expression, establishing an auto-regulatory negative feedback loop between Wnt4 and the EAF family conserved between zebrafish and mammals.\",\n      \"method\": \"Chromatin immunoprecipitation, reporter assay, morpholino knockdown and mRNA rescue in zebrafish, RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, combined with in vivo zebrafish rescue experiments; single lab\",\n      \"pmids\": [\"20161747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Combined loss of EAF2 and VHL heterozygosity cooperatively increases angiogenesis in mouse liver and prostate, with increased microvessel density and HIF-1alpha/VEGF staining. EAF2(-/-) VHL(+/-) mice show higher incidence of proliferative hepatic vascular lesions and prostatic intraepithelial neoplasia compared to either single mutant, demonstrating in vivo cooperation between EAF2 and VHL in angiogenic regulation.\",\n      \"method\": \"Mouse genetic cross (EAF2(-/-) x VHL(+/-)), immunohistochemistry, microvessel density quantification\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo compound knockout epistasis experiment with quantified angiogenic phenotypes; single lab\",\n      \"pmids\": [\"21638067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EAF1 and EAF2 inhibit canonical Wnt/beta-catenin signaling in zebrafish and cultured cells. By immunoprecipitation, Eaf1 and Eaf2 bind to the Armadillo repeat region and C-terminus of beta-catenin, and also interact with c-Jun, Tcf, and Axin, forming a novel complex. The N-terminus of Eaf1/Eaf2 binds beta-catenin and exhibits dominant-negative activity; the C-terminus contains a suppression domain or recruits a repressor. Both termini must be intact for full suppressive activity. Loss- and gain-of-function assays in zebrafish confirm modulation of mesodermal and neural patterning.\",\n      \"method\": \"Morpholino knockdown, mRNA injection, immunoprecipitation, beta-catenin reporter assay, deletion mutagenesis in zebrafish and cultured cells\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, reporter assay, in vivo loss/gain-of-function, domain mutagenesis) establishing direct interaction and mechanism; single lab but comprehensive\",\n      \"pmids\": [\"23364330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Concomitant loss of EAF2 and heterozygous loss of Pten synergistically promotes prostate cancer in mice (33% incidence), with elevated phospho-Akt, phospho-p44/42, increased microvessel density, and higher epithelial proliferation in intact and castrated EAF2(-/-)Pten(+/-) mice compared to single mutants. This demonstrates functional interaction between EAF2 and the PTEN/PI3K/Akt pathway in prostate carcinogenesis.\",\n      \"method\": \"Compound knockout mouse model (EAF2(-/-) x Pten(+/-)), immunohistochemistry, laser-capture microdissection with RT-PCR, proliferation analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo epistasis with compound knockout, multiple molecular readouts (p-Akt, p-MAPK, microvessel density, proliferation), validated in clinical specimens\",\n      \"pmids\": [\"23708662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Pirin was identified as a binding partner of EAF2 by yeast two-hybrid screening and confirmed by co-immunoprecipitation in mammalian cells. Overexpressed Pirin decreases EAF2 protein levels in prostate cancer cell lines and blocks EAF2-mediated growth inhibition of LNCaP cells, establishing Pirin as a regulator of EAF2 protein stability and function.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation, colony formation assay\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid confirmed by co-IP and functional assay; single lab with two orthogonal methods\",\n      \"pmids\": [\"24272884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EAF2 is a hypoxia-response gene containing a hypoxia response element (HRE) in its promoter. HIF-1alpha (but not HIF-2alpha) induces EAF2 expression under hypoxia. EAF2 in turn binds and suppresses HIF-1alpha (but not HIF-2alpha) transactivation by disrupting p300/CBP recruitment to HIF-1alpha, independently of FIH-1 and Sirt1. EAF2 also protects cells against hypoxia-induced cell death and inhibits cellular glucose uptake under hypoxia, establishing a negative feedback loop between EAF2 and HIF-1alpha.\",\n      \"method\": \"HRE reporter assay, co-immunoprecipitation, luciferase transactivation assay, pVHL-null cell lines (RCC4 and 786-O), glucose uptake assay, cell viability assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assay, co-IP, pVHL-null cell lines as mechanistic controls, glucose uptake, viability assays), isoform specificity demonstrated; single lab but rigorous\",\n      \"pmids\": [\"24421387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EAF2 co-immunoprecipitates with FOXA1 in human prostate cancer cells. EAF2 knockdown enhances endogenous FOXA1 protein levels, while GFP-EAF2 overexpression down-regulates FOXA1 protein. FOXA1 knockdown inhibits EAF2-knockdown-induced enhancement of AR target gene expression, cell proliferation, and migration in LNCaP cells, indicating that FOXA1 mediates EAF2 regulation of AR signaling, proliferation, and migration. The ortholog pha-4 (C. elegans FOXA1) was identified by RNAi screen in eaf-1 mutant worms as synergistically enhancing reduced fertility.\",\n      \"method\": \"Co-immunoprecipitation, protein stability assay, RNAi screen in C. elegans, RT-PCR, luciferase reporter assay, BrdU proliferation assay, transwell migration assay\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, protein stability, functional epistasis in two model systems (C. elegans and human cells), multiple cell-based assays; single lab\",\n      \"pmids\": [\"25808853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"EAF2 is selectively upregulated in germinal centre (GC) B cells and promotes their apoptosis both in vitro and in vivo. EAF2 deficiency results in enlarged GCs and elevated antibody production during T-dependent immune responses. EAF2-knockout mice develop severe collagen-induced arthritis with high autoantibody titers and spontaneously produce anti-dsDNA, rheumatoid factor, and anti-nuclear antibodies with age, demonstrating that EAF2-mediated apoptosis in GC B cells limits excessive humoral immune responses and maintains self-tolerance.\",\n      \"method\": \"EAF2 knockout mouse model, immunization assay, collagen-induced arthritis model, flow cytometry, apoptosis assay in vitro and in vivo\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with multiple defined immunological phenotypes and mechanistic readouts (GC size, antibody titers, autoantibodies, apoptosis), validated in two independent disease models\",\n      \"pmids\": [\"26935903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"EAF2 and EAF1 are required for the recruitment and retention of Ku70/Ku80 to DNA damage sites and play a functional role in nonhomologous end-joining (NHEJ) DNA repair. EAF2 knockdown sensitizes prostate cancer cells to DNA damage in a p53-independent manner, and EAF2 knockout mouse prostate is sensitized to gamma-irradiation. EAF2 knockdown blocks androgen-mediated repression of gamma-H2ax induction by doxorubicin, suggesting EAF2 mediates androgen protection against DNA damage via Ku70/Ku80.\",\n      \"method\": \"siRNA knockdown, EAF2 knockout mouse model, gamma-H2ax immunofluorescence, DNA damage sensitivity assay (doxorubicin, gamma-irradiation), NHEJ reporter assay, Ku70/Ku80 recruitment assay at DNA damage sites\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse and siRNA knockdown with defined molecular mechanism (Ku70/Ku80 recruitment), NHEJ functional assay, multiple cell lines and in vivo validation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"27721405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Concurrent knockdown of EAF2 and p53 in prostate cancer cells activates STAT3 signaling (increased p-STAT3), and STAT3 knockdown abrogates the stimulation of cell proliferation caused by co-knockdown of EAF2 and p53. EAF2(-/-)p53(-/-) mouse prostate shows significantly increased p-STAT3 immunostaining, establishing that EAF2 and p53 co-regulate STAT3 activation in prostate cancer.\",\n      \"method\": \"RNA-seq, siRNA knockdown, immunohistochemistry in mouse prostate (Eaf2-/-p53-/- model), human prostate cancer specimen immunostaining, cell proliferation assay\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — compound KO mouse model with molecular validation (RNA-seq, IHC), epistasis via STAT3 knockdown rescue, and human specimen correlation; single lab\",\n      \"pmids\": [\"29518696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Murine Eaf2 is preferentially expressed in the central nervous system, sensory and neuroendocrine organs during embryogenesis. In the developing lens, Eaf2 is absent from proliferating anterior lens epithelial cells but present in terminally differentiated primary lens fiber cells and non-proliferating lens fiber cells in the equatorial zone, suggesting a role in regulating lens cell differentiation and maturation.\",\n      \"method\": \"In situ hybridization during mouse embryogenesis, spatial expression analysis\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (in situ hybridization) establishing localization/expression without direct functional experiment\",\n      \"pmids\": [\"14517999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RNAi-mediated silencing of EAF2 in HCT-116 colon cancer cells modulates cellular response to both simvastatin and lovastatin, as validated by functional RNAi experiments following bioinformatic identification of EAF2 from NCI60 panel data.\",\n      \"method\": \"Bioinformatic analysis of NCI60 SNP data, RNAi functional validation in HCT-116 cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single RNAi validation experiment with phenotypic readout only (drug response), no pathway mechanism established\",\n      \"pmids\": [\"21483694\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EAF2 is an androgen-regulated tumor suppressor that functions as a component of the ELL RNA polymerase II transcription elongation complex, where ELL binding controls EAF2 nuclear localization, stability, and transactivation; EAF2 suppresses tumorigenesis through multiple mechanisms including: binding and stabilizing pVHL to restrict HIF-1alpha activity and angiogenesis, directly binding beta-catenin and its co-factors to inhibit canonical Wnt signaling, forming a negative feedback loop with Wnt4, disrupting p300 recruitment to HIF-1alpha, co-regulating p53 and STAT3 signaling, promoting Ku70/Ku80-dependent nonhomologous end-joining DNA repair, and inducing apoptosis in germinal centre B cells to suppress autoimmunity; in vivo knockout models demonstrate EAF2 loss leads to multi-organ tumorigenesis, excessive humoral immune responses, and synergistic carcinogenesis with PTEN loss.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EAF2 is an androgen-regulated tumor suppressor that originates as a component of the ELL RNA polymerase II transcription elongation machinery, binding the amino-terminal domain of ELL through a region (residues 68–113) that also carries its growth-suppressive and apoptotic activity [#0, #3]. ELL binding governs EAF2 nuclear speckle formation, protein stability, and transactivation, coupling the elongation partnership to EAF2 function [#2]. Its tumor-suppressive role is established in vivo: germline knockout produces multi-organ tumorigenesis including lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma, and prostatic intraepithelial neoplasia, alongside cell-size and proliferation defects [#4], and EAF2 loss cooperates with Pten heterozygosity to drive prostate cancer through PI3K/Akt activation [#11]. EAF2 restrains angiogenesis through two convergent mechanisms: it binds and stabilizes pVHL to limit HIF-1alpha accumulation and activity [#5, #9], and it directly binds and selectively suppresses HIF-1alpha transactivation by disrupting p300/CBP recruitment within a hypoxia-driven negative feedback loop [#13]. EAF2 inhibits canonical Wnt/beta-catenin signaling by binding the Armadillo region and C-terminus of beta-catenin together with c-Jun, Tcf, and Axin, while participating in an autoregulatory feedback loop with noncanonical Wnt4/Wnt11/Wnt5 signaling that controls morphogenetic movements and patterning [#10, #8, #7]. Additional tumor-suppressive and homeostatic outputs include co-regulation of p53-dependent thrombospondin-1 expression and STAT3 activation [#6, #17], promotion of Ku70/Ku80-dependent nonhomologous end-joining repair [#16], modulation of androgen receptor signaling via FOXA1 [#14], and induction of germinal-centre B-cell apoptosis to limit autoimmunity [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established EAF2's molecular identity by showing it is a dedicated partner of the ELL elongation factor with its own transcriptional activation domain, placing it in the RNA Pol II elongation machinery.\",\n      \"evidence\": \"Reciprocal Co-IP from multiple cell lines, confocal co-localization, deletion mapping, and transactivation assays\",\n      \"pmids\": [\"12446457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish endogenous target genes regulated by the EAF2-ELL complex\", \"Physiological role beyond elongation partnership unaddressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapped EAF2's developmental expression to neural and sensory tissues and differentiated lens fibers, hinting at a role in cell differentiation.\",\n      \"evidence\": \"In situ hybridization across mouse embryogenesis\",\n      \"pmids\": [\"14517999\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Expression-only data with no functional perturbation\", \"No mechanism linking EAF2 to lens differentiation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Positioned EAF2 downstream of noncanonical Wnt-4 signaling in eye development, linking its elongation-factor activity to a developmental pathway.\",\n      \"evidence\": \"Morpholino knockdown, mRNA rescue, and in situ hybridization in Xenopus\",\n      \"pmids\": [\"15775981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes of EAF2 in eye specification not defined\", \"Mammalian relevance of the Wnt4-EAF2 axis not yet tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed that ELL binding is not just structural but controls EAF2 localization, stability, and activity, establishing the partnership as functionally regulatory.\",\n      \"evidence\": \"Co-transfection, Co-IP, protein stability and transactivation assays in prostate cells\",\n      \"pmids\": [\"16114057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of ELL-dependent stabilization (e.g., protection from degradation) not resolved\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined a minimal EAF2 region required for both ELL binding and tumor suppression, and demonstrated EAF2 is a bona fide tumor suppressor in vivo.\",\n      \"evidence\": \"Deletion mutants with colony formation/apoptosis assays; multi-organ tumor phenotyping in EAF2 knockout mice\",\n      \"pmids\": [\"17044034\", \"17873910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular drivers of each tissue-specific tumor type not dissected\", \"Link between elongation activity and tumor suppression unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified pVHL stabilization and p53/TSP-1 regulation as anti-angiogenic mechanisms, mechanistically connecting EAF2 loss to increased HIF-1alpha and vascular abnormalities.\",\n      \"evidence\": \"Co-IP, in vitro binding, pulse-chase stability, Matrigel plug assays in knockout mice; luciferase reporter and IHC for p53/TSP-1\",\n      \"pmids\": [\"19258512\", \"19826414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How EAF2 stabilizes pVHL biochemically not defined\", \"Relative contribution of pVHL vs p53 routes to angiogenesis unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed EAF family upstream of noncanonical Wnt (wnt11/wnt5) signaling controlling convergence-extension, expanding EAF2's role in morphogenesis.\",\n      \"evidence\": \"Morpholino knockdown, mRNA rescue, cell tracing, and epistasis in zebrafish\",\n      \"pmids\": [\"19380582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets among wnt genes not shown in this study\", \"Redundancy between EAF1 and EAF2 not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated direct EAF binding to the Wnt4 promoter, establishing an autoregulatory Wnt4-EAF negative feedback loop conserved across species.\",\n      \"evidence\": \"ChIP, reporter assays, and zebrafish knockdown/rescue\",\n      \"pmids\": [\"20161747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-factors mediating promoter repression not identified\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided in vivo genetic evidence that EAF2 and VHL cooperate to restrain angiogenesis, and connected EAF2 to drug-response phenotypes.\",\n      \"evidence\": \"EAF2(-/-) x VHL(+/-) compound mouse cross with microvessel quantification; separate RNAi statin-response screen in HCT-116\",\n      \"pmids\": [\"21638067\", \"21483694\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Statin-response link is phenotype-only with no mechanism (Low confidence)\", \"Tissue specificity of EAF2-VHL cooperation not explained\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved EAF2's mechanism of canonical Wnt inhibition and its synergy with PTEN loss in carcinogenesis, integrating Wnt and PI3K/Akt axes into its tumor-suppressive program.\",\n      \"evidence\": \"Co-IP, beta-catenin reporter, domain mutagenesis in zebrafish/cells; EAF2(-/-) x Pten(+/-) compound mouse model with IHC and proliferation readouts\",\n      \"pmids\": [\"23364330\", \"23708662\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether beta-catenin binding requires the ELL partnership not tested\", \"C-terminal repressor identity in the beta-catenin complex unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified Pirin as a negative regulator of EAF2 stability, revealing a route by which EAF2 tumor-suppressive function can be downmodulated.\",\n      \"evidence\": \"Yeast two-hybrid screen, Co-IP, and colony formation rescue\",\n      \"pmids\": [\"24272884\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which Pirin destabilizes EAF2 not defined\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established a direct EAF2-HIF-1alpha negative feedback loop independent of pVHL, showing isoform-specific suppression of HIF-1alpha via blockade of p300/CBP recruitment.\",\n      \"evidence\": \"HRE reporter, Co-IP, transactivation assays in pVHL-null cells, glucose uptake and viability assays\",\n      \"pmids\": [\"24421387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of HIF-1alpha vs HIF-2alpha selectivity unresolved\", \"Interplay between the pVHL-dependent and pVHL-independent HIF routes not integrated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected EAF2 to androgen receptor signaling by showing it suppresses FOXA1, which mediates EAF2 control of AR target genes, proliferation, and migration.\",\n      \"evidence\": \"Co-IP, protein stability assays, C. elegans RNAi epistasis, and cell-based proliferation/migration assays\",\n      \"pmids\": [\"25808853\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of FOXA1 downregulation by EAF2 not defined\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined EAF2's DNA-repair and immune-homeostasis functions, showing it promotes Ku70/Ku80-dependent NHEJ and drives germinal-centre B-cell apoptosis to prevent autoimmunity.\",\n      \"evidence\": \"siRNA and knockout mouse models with gamma-H2ax IF, NHEJ reporter, Ku recruitment assays; immunization and collagen-induced arthritis models with flow cytometry and apoptosis assays\",\n      \"pmids\": [\"27721405\", \"26935903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How EAF2 recruits/retains Ku70/Ku80 mechanistically is unresolved\", \"Trigger of EAF2 upregulation in GC B cells unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed that EAF2 and p53 jointly restrain STAT3 activation, adding an oncogenic-signaling axis to EAF2's tumor-suppressive network in prostate cancer.\",\n      \"evidence\": \"RNA-seq, siRNA knockdown with STAT3 rescue, IHC in EAF2(-/-)p53(-/-) mouse prostate and human specimens\",\n      \"pmids\": [\"29518696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism linking EAF2/p53 loss to STAT3 phosphorylation not defined\", \"Single-lab data\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How EAF2's core RNA Pol II elongation activity mechanistically unifies its diverse partner interactions (pVHL, HIF-1alpha, beta-catenin, Ku70/80, FOXA1) into a single tumor-suppressive program remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of EAF2 bound to its multiple partners\", \"Whether transcriptional elongation activity is required for each non-transcriptional function untested\", \"No unified picture of which interactions are direct versus complex-mediated in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 13]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 13, 10]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 13, 17]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"complexes\": [\n      \"ELL elongation complex\",\n      \"beta-catenin/c-Jun/Tcf/Axin complex\"\n    ],\n    \"partners\": [\n      \"ELL\",\n      \"VHL\",\n      \"HIF1A\",\n      \"CTNNB1\",\n      \"TP53\",\n      \"FOXA1\",\n      \"PIR\",\n      \"XRCC6\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}